A Randomized, Double-Blind, Placebo-Controlled Phase II Trial Investigating the Safety and Immunogenicity of Modified Vaccinia Ankara Smallpox Vaccine (MVA-BN®) in 56-80-Year-Old Subjects

BACKGROUND: Modified Vaccinia Ankara MVA-BN(®) is a live, highly attenuated, viral vaccine under advanced development as a non-replicating smallpox vaccine. In this Phase II trial, the safety and immunogenicity of Modified Vaccinia Ankara MVA-BN(®) (MVA) was assessed in a 56–80 years old population....

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:PLoS One
Main Authors: Greenberg, Richard N., Hay, Christine M., Stapleton, Jack T., Marbury, Thomas C., Wagner, Eva, Kreitmeir, Eva, Röesch, Siegfried, von Krempelhuber, Alfred, Young, Philip, Nichols, Richard, Meyer, Thomas P., Schmidt, Darja, Weigl, Josef, Virgin, Garth, Arndtz-Wiedemann, Nathaly, Chaplin, Paul
Formato: Artigo
Idioma:Inglês
Publicado em: Public Library of Science 2016
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4915701/
https://ncbi.nlm.nih.gov/pubmed/27327616
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0157335
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados